# Tmunity Therapeutics

> Next-generation CAR-T cell therapy biotech from Penn Medicine.

## Why it is interesting

Carl June/Bruce Levine cell-therapy lineage — a16z-led $75M B before Gilead/Kite buyout.

## Profile

- **Stage:** acquired
- **Status:** acquired
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series B (2019): $75M led by a16z; Kleiner Perkins participated (a16z announcement)
- Exit (2023): acquired by Gilead/Kite (Gilead press)

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/kleiner-perkins

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/tmunity-therapeutics